Regeneron Pharmaceuticals (REGN) is a U.S.-based biotech company focused on manufacturing novel biologics. The companyâs recent share price rally was facilitated by strong 3rd quarter results, with sales increasing 23% and net income improving 13% year-on-year. A key factor behind these strong results was an increase in Dupixent sales by 141%. This drug was launched in partnership with Sanofi, and was recently approved to treat eczema in children in Europe – something that is expected to add to companyâs sales and profitability going forward.
We step back from these recent swings to review Regeneron PharmaceuticalsÂ performance over the last few years, as a context for what might come next. Our Interactive dashboard – Why has Regeneron Pharmaceuticals’ stock rallied by 25% over last 2 months?,Â reviews the near term reasons and the big picture.
The context for the last few years:
A closer look At Regeneron PharmaceuticalsÂ Total Revenues over the last few years and the outlook
Revenues for Regeneron Pharmaceuticals increased from $5.87 Bil in 2017 to $6.71 Bil in 2018 – a 14.3% increase.
This compares with Revenues growth of:
- 18.4% in 2016
- 20.8% in 2017
We expect Revenues growth to be 15.9% in 2019.
A closer look At Regeneron PharmaceuticalsÂ Total ExpensesÂ over the last few years and the outlook
Total Expense for Regeneron Pharmaceuticals increased from $3.8 Bil in 2017 to $4.2 Bil in 2018 – an increase of 10.1%.
This compares with Total Expense growth of:
- 23.4% in 2016
- 7.9% in 2017
We expect Total Expense to grow by 7.5% in 2019.
How doesÂ Regeneron PharmaceuticalsÂ Revenue Growth compare with rivals?
For more information on how Regeneron PharmaceuticalsâÂ revenue growth compares with Biogen, Celgene Corporation and Alexion Pharmaceuticals, view our interactive dashboard analysis.
How has Â Regeneron PharmaceuticalsÂ EBT trended?
Earnings Before Taxes (EBT) for Regeneron Pharmaceuticals increased from $2.1 Bil in 2017 to $2.55 Bil in 2018 – an increase of 22.9%.
This compares with EBT growth of:
- 8.5% in 2016
- 56.3% in 2017
We expect EBT growth to be 27.6% in 2019.
How has Regeneron PharmaceuticalsÂ Net Income and EPS trended?
For more details aboutÂ Regeneron Pharmaceuticalsâ Net Income and EPS, view our interactive dashboard analysis
Whatâs behind Trefis? See How itâs Powering New Collaboration and What-Ifs
ForÂ CFOs and Finance TeamsÂ |Â Product, R&D, and Marketing Teams
More Trefis Data
Like our charts? ExploreÂ example interactive dashboardsÂ and create your own.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.